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Factors associated with duration of dementia in a consecutive series of 103 Alzheimer’s disease (AD) cases were studied using the
Kaplan-Meier estimator and Cox regression analysis (proportional hazard model). Mean disease duration was 7.1 years (range: 6
weeks–30 years, standard deviation = 5.18); 25% of cases died within four years, 50% within 6.9 years, and 75% within 10 years.
Familial AD cases (FAD) had a longer duration than sporadic cases (SAD), especially cases linked to presenilin (PSEN) genes.
No significant differences in duration were associated with age, sex, or apolipoprotein E (Apo E) genotype. Duration was reduced
in cases with arterial hypertension. Cox regression analysis suggested longer duration was associated with an earlier disease
onset and increased senile plaque (SP) and neurofibrillary tangle (NFT) pathology in the orbital gyrus (OrG), CA1 sector of
the hippocampus, and nucleus basalis of Meynert (NBM). The data suggest shorter disease duration in SAD and in cases with
hypertensive comorbidity. In addition, degree of neuropathology did not influence survival, but spread of SP/NFT pathology into
the frontal lobe, hippocampus, and basal forebrain was associated with longer disease duration.
1. Introduction
Studies of the life expectancy of patients with Alzheimer’s
disease (AD) are important in calculating prevalence rates
while identifying factors that influence survival is useful both
in counseling patients and their families and in public health
planning [1–3].Manypublished studies, however, suggest that
survival rates vary considerably inADand depend on numer-
ous factors [3]. Hence, survival may depend on age at diag-
nosis, sex, disease subtype, and severity of progression of the
disease.
AD is a heterogeneous disease [4–6] and survival may
depend on subtype [7]. First, AD consists of sporadic (SAD)
and familial forms (FAD), most cases of the latter being
associated with mutations of either the amyloid precursor
protein (APP) gene on chromosome 21 [8, 9] or the presenilin
genes PSEN1 [10] and PSEN2 [11] on chromosomes 14 and 1,
respectively. In addition, allelic variation in the apolipoprotein
E (Apo E) gene on chromosome 19 has been identified as
an important risk factor, especially in late-onset AD individu-
als having 2-3 times the frequency of allele 𝜀4 compared with
nondemented elderly controls [12]. Second, more complex
forms of AD have been described, for example, AD in combi-
nation with parkinsonism [13] or dementia with Lewy bodies
(DLB/AD) [14], with significant degeneration of white matter
[15] or with capillary amyloid angiopathy (CAA). Hence,
the presence of one or more comorbidities may significantly
affect survival of AD patients. Third, studies suggest at least
two distinct types of disease progression in AD, namely, a
rapidly progressive subtype with a median survival time of 10
months and a subtype characterized by a much slower pro-
gression [16–18].
The objective of the present study was to investigate the
relationship between genetics, demography, neuropathology,
comorbidity, and disease duration in 103 AD cases. The
Kaplan-Meier estimator andCox regression analysis (propor-
tional hazardmodel) were used to study the survival function
of the AD patients and to test specific hypotheses [19–21].
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 623487, 7 pages
http://dx.doi.org/10.1155/2014/623487
2 BioMed Research International
Table 1: Demographic details of the 103 cases used in the study (𝑁: number of cases; FAD: familial Alzheimer’s disease; SAD: sporadic
Alzheimer’s disease). Data for age at death, duration, and disease onset are means with range and standard deviations in parentheses.
Patient group 𝑁 Age at death (years) Duration (years) Onset (years)
Early-onset FAD 19 61.9 (46–74, 10.8) 11.1 (3–20, 6.5) 50.7 (38–59, 6.5)
Early-onset SAD 22 70.4 (57–88, 11.1) 16.0 (6–30, 9.3) 54.4 (49–58, 4.2)
Late-onset FAD 12 77.4 (70–85, 5.1) 7.0 (1–15, 4.6) 70.4 (61–84, 7.6)
Late-onset SAD 50 80.1 (70–98, 6.6) 6.8 (1–21, 4.5) 73.5 (62–93, 7.2)
2. Materials and Methods
2.1. Cases. The study population comprised a series of 103
consecutive cases ofADdiagnosed at theDepartment ofNeu-
ropathology,University ofWashington, Seattle, USA (Table 1)
[6]. Informed consent was given for the removal of all brain
tissue according to the Declaration of Helsinki. AD cases all
fulfilled “National Institute of Neurological andCommunica-
tive Disorders and Stroke and the Alzheimer Disease and
Related Disorders Association” (NINCDS/ADRDA) criteria
for probable AD [22] and were neuropathologically verified
using “Consortium to Establish a Registry of Alzheimer Dis-
ease” (CERAD) criteria [23] and National Institute on Aging
and Reagan Institute criteria [24]. All cases conformed to
stage V or VI of the Braak staging system [25, 26].The family
history of all cases was examined and those with at least one
or more first-degree relatives affected were regarded as FAD.
Disease duration was measured from the onset of dementia,
which was determined by clinical assessment, and defined as
cognitive dysfunction sufficiently severe to impair activities
of daily living. Of the 103 cases, 19/103 (18%) were early-
onset (≤65 yrs) FAD, 12/103 (11.6%) were late-onset (>65 yrs)
FAD, 22/103 (21%) were early-onset SAD, and 50/103 (49%)
were late-onset SAD. Nine of the early-onset FAD cases were
linked to PSEN genes, four cases to PSEN1, and five cases to
PSEN2.Apo E genotypewas determined for a subset of 40/103
of the cases with the following distribution of genotypes: 𝜀2/3
(𝑛 = 1), 𝜀3/3 (𝑛 = 12), 𝜀2/4 (𝑛 = 3), 𝜀3/4 (𝑛 = 18), and 𝜀4/4
(𝑛 = 6).
2.2. Neuropathology. Total brain weight was measured at
postmortem. In addition, the abundance of senile plaques
(SP) and neurofibrillary tangles (NFT), the signature patho-
logical lesions of AD [23, 27], wasmeasured in 22 cortical and
subcortical brain areas from each case (Table 2). The quanti-
tative assessment of SP and NFT was based on examination
of tissue sections stained by silver impregnation methods
(Holmes, Bielschowsky) which stain mature “neuritic” and
“classic” SP and NFT [6]. Preamyloid or diffuse plaques are
not consistently labeled by these methods. In each region, 10,
50 × 50𝜇m sample fields were located at random. The abun-
dance of SP and NFT within each field was assessed using a
semiquantitative scale [28]: 0 = none, 1 = mild, 2 = moderate,
and 3 = severe. The abundance scores of the SP and NFT
were averaged to give a single abundance score for each brain
area and rounded up to the nearest whole number.The mean
abundance score of the SP/NFT derived from all brain areas
studied was used as a measure of the overall severity of the
pathology in each case.
Table 2: Brain regions and areas studied.
Brain region Area studied Abbreviation
Frontal
Superior frontal gyrus SFG
Orbital gyrus OrG
Gyrus rectus GyR
Cingulate gyrus CgG
Perisylvian Insula/claustrum In/Cl
Temporal
Superior temporal gyrus STG
Parahippocampal gyrus PHG
Hippocampus, CA1 CA1
Dentate gyrus DG
Amygdala Am
Parietal Superior parietal lobe SPL
Occipital Visual cortex (B17/B18) OC
Subcortical
Thalamus Th
Lateral geniculate nucleus LGN
Basal ganglia BG
Substantia nigra SN
Nucleus basalis of Meynert NBM
Ventral tegmentum VT
Raphe nucleus RaN
Mamillary bodies MB
Hypothalamus HyP
Cerebellum CB
2.3. Comorbidity. Comorbidity data [4] were obtained from
postmortem records and divided into two groups: (1) neu-
rological comorbidity, for example, associated parkinsonism,
amyotrophic lateral sclerosis (ALS), Pick’s disease (PiD),
Creutzfeldt-Jakob disease (CJD), stroke, infarct, aneurysm,
hydrocephalus, motor neuron disease (MND), or tumor, and
(2) nonneurological comorbidity, for example, cardiovascular
disease (CVD), arterial hypertension, respiratory disease,
malignant disease, diabetes, and anemia. A number of aspects
of comorbidity were tested against survival of AD patients:
(1) the presence or absence of a neurological or nonneu-
rological comorbidity, (2) the frequency of neurological or
nonneurological comorbidities recorded for each case, and
(3) the individual types of neurological and nonneurological
comorbidity which were present in at least six cases.
2.4. Data Analysis. The Kaplan-Meier estimator (“product
limit estimator”) was used to study the overall pattern of sur-
vival among the 103 cases and is the fraction of patients which
survive for a certain period after onset of dementia. In typical
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applications, the data can be grouped into subtypes and the
effect of the grouping factor on disease duration estimated.
Where two groups were present, for example, FAD/SAD,
male/female, or presence/absence of comorbidity, duration
was compared using the Gehan-Wilcoxon two-sample test.
With more than two groups, duration was compared using
the chi-square (𝜒2) test. The Cox proportional hazard model
allows the relationship between disease duration and contin-
uously measured variables to be tested and was applied to
(1) demographic variables such as patient age and disease
onset, genetic factors such as Apo E score (the sum of the
two alleles), and the frequency of one or more neurological
and nonneurological comorbidities, (2) measures of overall
neuropathology such as mean severity score and the number
of brain areas affected by SP/NFT, and (3) abundance scores
of SP and NFT in each of the 22 brain areas investigated. The
effect of disease onset may be biased by the presence of cases
linked to PSEN mutations, and hence, the effect of this vari-
able was also assessed with the PSEN mutation cases omitted.
Statistical significance was based on “𝑡” and the “Wald”
statistic.
3. Results
Mean disease duration of the 103 AD cases was 7.1 years
(range: 6 weeks–30 years, standard deviation = 5.18). The
survival function for all 103 cases studied is shown in Figure 1.
The data indicate that 25% of cases died within four years,
50% within 6.9 years, and 75% within 10 years after onset.
Gehan-Wilcoxon test suggested a significant difference in
disease duration between SAD and all FAD cases (G-W =
2.51, 𝑃 < 0.05). When cases were separated into SAD, cases
linked to PSEN mutations, and all remaining FAD (Figure 2),
the PSEN cases, on average, exhibited the greatest disease
duration (𝜒2 = 7.13, 𝑃 < 0.01). There were no significant dif-
ferences in durationwhen the datawere grouped according to
sex (G-W = 0.58, 𝑃 > 0.05), the presence/absence of neu-
rological comorbidity (G-W = 0.51, 𝑃 > 0.05), or individual
types of neurological comorbidity (𝜒2 = 12.15, 𝑃 > 0.05).
Similarly, the presence of a nonneurological comorbidity did
not affect overall duration (G-W = 0.78, 𝑃 > 0.05). Never-
theless, when data were grouped according to the presence
of CVD, arterial hypertension, or neither of these, duration
was reduced in the hypertensive group (Figure 3) (𝜒2 = 8.50,
𝑃 < 0.05).
The results of the Cox regression analysis for demo-
graphic variables, Apo E genotype, and the neuropathologi-
cal variables are shown in Table 3. The data suggest that
(1) patient age had no significant effect on duration, (2) dis-
ease onset was significantly associated with duration, early-
onset cases exhibiting better survival (𝑡 = 4.12,Wald statistic =
16.98, and 𝑃 < 0.01), (3) Apo E score and brain weight were
unrelated to duration, and (3) neither total number of areas
affected by SP/NFT nor overall severity of pathology was
significantly related to duration. The effect of disease onset
was similar regardless of whether the PSEN mutation cases
were included in the analysis (𝑡 = 4.75, 𝑃 < 0.001).
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Figure 1: Kaplan-Meier survival function of all 103 Alzheimer’s
disease (AD) patients.
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Figure 2: Kaplan-Meier survival function of the data grouped into
familial Alzheimer’s disease (FAD), sporadic Alzheimer’s disease
(SAD), and familial cases linked to presenilin (PSEN) mutations
(comparison between groups: 𝜒2 = 7.13, 𝑃 < 0.01).
The results of the Cox regression analysis of the SP/NFT
scores from each brain area studied are shown in Table 4.
Of the 22 areas examined, increasing disease duration was
associated with increased abundance scores of SP/NFT in
three specific areas, namely, the orbital gyrus (OrG) (𝑡 = 2.03,
Wald statistic = 4.12, and 𝑃 < 0.05), CA1 sector of the hip-
pocampus (𝑡 = 2.04, Wald statistic = 4.18, and 𝑃 < 0.05), and
nucleus basalis of Meynert (NBM) (𝑡 = 2.09, Wald statistic =
4.38, and 𝑃 < 0.05).
4. Discussion
Mean disease duration of the 103 AD cases studied was 7.1
years slightly higher than the 5.2 years and 6.5 years recorded
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Figure 3: Kaplan-Meier survival function of the data grouped
into those Alzheimer’s disease (AD) patients with no associated
signs of cardiovascular disease (NONE), those with the signs of
cardiovascular disease (CVD), and those with arterial hypertension
(HYPER) (comparison between groups: 𝜒2 = 8.50, 𝑃 < 0.05).
Table 3: Results of the Cox proportional hazard model analysis
for demographic, apolipoprotein E (Apo E) score, overall severity
of neuropathology, and comorbidity (the frequency of neurological
and nonneurological comorbidities present in each case).
Variable 𝛽 SE 𝑡 Wald 𝑃
Patient age −0.005 0.01 0.47 0.99 0.64
Disease onset (all cases) 0.049 0.01 4.12 16.98 0.008∗∗
Disease onset
(minus PSEN cases) 0.055 0.012 4.75 22.61 <0.001
Brain weight 0.001 0.0009 0.62 0.38 0.54
Apo E score 0.079 0.27 0.29 0.08 0.77
Number of areas affected −0.002 0.056 0.04 0.001 0.97
Overall severity score −0.011 0.058 0.19 0.03 0.85
Neurological
comorbidity 0.131 0.136 0.96 0.93 0.33
Nonneurological
comorbidity 0.032 0.081 0.40 0.16 0.70
𝛽: regression coefficient; SE: standard error; 𝑃: probability; ∗∗𝑃 < 0.01.
by Doody et al. [29] and Feldman et al. [30], respectively.The
data also contrast with those reported for a specific group of
AD cases, namely, those with vascular disease comorbidity,
in which mean survival was less than five years [30], and
semantic dementia (SD), in which 50% of patients survived
more than 12.8 years [20]. In addition, although controversial,
recent evidence supports the presence of two distinct sub-
types of AD progression [17], cases having either a very short
(median survival 10 months) or a significantly longer disease
duration. AD cases with very short durations were evident
in the present sample, 10 cases surviving two years or less. A
multiple discriminant analysis comparing these 10 cases with
Table 4: Results of the Cox proportional hazard model analysis for
abundance scores of senile plaques (SP) and neurofibrillary tangles
(NFT) in each brain region.
Area 𝛽 SE 𝑡 Wald 𝑃
Superior frontal gyrus −0.00329 0.01 0.31 0.098 0.75
Cingulate gyrus −0.00998 0.02 0.44 0.99 0.66
Orbital gyrus 0.02039 0.01 2.03 4.12 0.04∗
Gyrus rectus −0.1717 0.03 0.62 0.98 0.53
Amygdala 0.01040 0.01 1.31 1.01 0.19
Dentate gyrus 0.00544 0.03 0.19 1.00 0.85
Insula −0.00252 0.01 0.26 0.07 0.79
Claustrum 0.03414 0.02 1.71 2.92 0.09
Parahippocampal gyrus −0.00190 0.01 0.17 0.03 0.86
Hippocampus CA1 0.03575 0.02 2.04 4.18 0.04∗
Superior temporal gyrus 0.00699 0.01 0.74 0.55 0.46
Ventral tegmentum 0.00470 0.02 0.26 1.00 0.80
Raphe nucleus −0.02172 0.02 1.11 1.24 0.27
Substantia nigra 0.02086 0.04 0.47 0.22 0.64
Thalamus −0.02530 0.02 1.58 2.51 0.11
Visual cortex (B17/B18) −0.00912 0.01 0.98 0.95 0.33
Superior parietal −0.01378 0.01 1.42 2.02 0.15
Nucleus basalis of Meynert 0.03978 0.02 2.09 4.38 0.04∗
Mamillary bodies 0.01486 0.02 0.78 0.59 0.44
Hypothalamus 0.01424 0.02 063 0.40 0.53
Basal ganglia −0.02667 0.02 1.17 1.37 0.24
Cerebellar cortex −0.0297 0.02 1.41 1.97 0.16
𝛽: regression coefficient; SE: standard error; 𝑃: probability; ∗𝑃 < 0.05.
the remainder suggested that short duration was not related
to age, onset, brain weight, neuropathology, or comorbidity.
The rapidly progressive form of AD has been linked to
increased levels of education and to be associated with amore
global cognitive impairment [31]. In addition, a strong corre-
lation between AD survival and rate of cognitive decline was
reported by Hui et al. [32]. By contrast, Bruandet et al. [33]
found that highly educated individuals with AD had a faster
rate of cognitive decline but did not have reduced survival
times. A limitation of the study is that no accurate data were
available on the education level of sufficient cases to test this
hypothesis. Alternatively, timing to onset of clinical diagnosis
may be related to undiagnosed pathology such as vascular
disease or spongiform change.
No significant differences in duration were observed
between males and females. This result contrasts with some
earlier studies which often show poorer survival in males
[1, 29, 34, 35]. However, the data suggested longer disease
duration in FAD than SAD, especially in cases linked to PSEN
mutations. Variation in survival rates between FAD and SAD
could result fromdifferences in neuropathology. Hence, cases
linked to PSEN1 have greater numbers of SP and NFT com-
pared with cases of SAD [36] but this increased pathology
would be expected to shorten survival rates. In addition,
many studies suggest that FAD and SAD have essentially the
same pathology [37–39]. The most likely explanation for the
longer duration of the FAD cases is either earlier disease onset
or reduced survival in SAD as a consequence of comorbidity.
BioMed Research International 5
Various types of neurological comorbidity were not
associated with shorter durations, in contrast with the study
of Feldman et al. [30], which showed reduced survival in
cases with associated vascular dementia. Similarly, the pres-
ence/absence of nonneurological comorbidity did not reduce
survival. In previous studies, the presence of at least one dis-
ease complication decreased lifespan inAD [40] and the pres-
ence of comorbidity and functional disability was an impor-
tant predictor of survival [21]. Bowen et al. [1] found a strong
association between decreased survival in AD and vascular
disease which is regarded as a significant determinant of pro-
gression to dementia. A limitation of the present study is that
accurate quantitative data on CVD load, for example, lacu-
nar infarcts, microinfarcts, and atherosclerosis of large ves-
sels, was not available. However, in the present study, the
presence/absence of CVD was not associated with disease
duration. Nevertheless, there was evidence of reduced disease
duration in those AD cases with arterial hypertension when
compared with those with CVD or neither of these condi-
tions.Hypertension is a strong risk factor for stroke, heart dis-
ease, aneurysm, and chronic kidney disease but the sample of
cases was too small to test whether hypertensive individuals
had increased incidence of these pathologies. A strong
correlation between the presence of atherosclerosis and
mortality in AD [41] and between survival and severe arterial
hypertension, measured at the beginning of the study [19],
has been demonstrated in AD. By contrast,Weiner and Risser
[42] found no effect of CVD or hypertension on AD survival.
In addition, no association between survival and CVD was
found in a cohort of Down’s syndrome (DS) patients [43],
who frequently develop AD-type pathology [44–46].
No association was observed between disease duration
and Apo E genotype of the patient. This is surprising as the
presence of allele 𝜀4 often accelerates the development of AD
pathology [47] and hence is associated with an earlier disease
onset [48]. Apo E genotype was available for only 40 of the
cases studied, which was too small a sample size to determine
the true effect of this variable. In the rapidly progressive
form of AD, however, no association with Apo E allele 𝜀4
and survival was reported [18]. By contrast, Tilvis et al. [49]
found that the presence ofApo E 𝜀4 allele was associated with
impaired cognitive function and clinical dementia and hence
could be associated with reduced survival.
Whether the degree of brain atrophy and weight signifi-
cantly change over the course of AD has been controversial.
There are significant limitations in studying this complex
variable as many factors may influence brain weight such as
height of the subject and the degree of osteoporosis. In one
study, poorer survival was associated with lower gray matter
volume and smaller volume reductions in brain predicted
better survival [50]. In the present study, no relationship
between brain weight and disease duration was demon-
strated. In addition, neither total number of areas affected by
SP/NFT pathology nor an overall measure of severity of the
pathology was associated with disease duration suggesting
neuropathology does not directly affect survival. Neverthe-
less, data suggest an association between SP/NFT pathology
in the OrG, sector CA1 of the hippocampus, and NBM and
longer disease durations consistent with spread of the pathol-
ogy into these areas later in the disease. Alternatively, correla-
tion of longer duration to pathology may result from regions
being the earliest affected and therefore exposed to accumu-
lating pathology over periods of time. Several studies suggest
that the pathology of AD may spread through the brain via
anatomical connections from an origin in the temporal lobe
to the cortical association areas and hippocampus and then
to the primary sensory areas [51–55]. In addition, pathogenic
proteins, such as tau, 𝛼-synuclein, and 𝛽-amyloid (A𝛽), can
be secreted from cells, enter other cells, and seed small intra-
cellular aggregates within these cells [56, 57] and therefore
could spread through the brain.
In conclusion, the data suggest disease duration of AD
patients is reduced in SAD and especially in cases with asso-
ciated arterial hypertension. By contrast, sex, neurological
comorbidity, brain weight,Apo E genotype, and neuropathol-
ogy had little effect on survival. Longer duration cases, how-
ever, were associated with spread of SP/NFT pathology into
the frontal lobe, hippocampus, and basal forebrain.
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